Skip to main content

Day: May 10, 2023

Marathon Digital Holdings Reports First Quarter 2023 Results

FORT LAUDERDALE, Fla., May 10, 2023 (GLOBE NEWSWIRE) — Marathon Digital Holdings, Inc. (NASDAQ: MARA) (“Marathon” or “Company”), a leader in supporting and securing the Bitcoin ecosystem, reported its financial and operational results for the first quarter ended March 31, 2023. First Quarter 2023 Financial ResultsThe Company recorded a net loss of $(7.2) million, or $(0.05) per share, during the fiscal quarter ended March 31, 2023, compared to a net loss of $(12.9) million, or $(0.12) per share, in the prior-year period ended March 31, 2022. Revenues were $51.1 million for the quarter, slightly below prior year revenues of $51.7 million, as a 74% increase in bitcoin production was more than offset by lower bitcoin prices in the current year period. The company recorded gains on the sale of bitcoin of $17.6...

Continue reading

NanoXplore Announces Record Adjusted EBITDA in Its Third Quarter and Raises Revenue Outlook

MONTREAL, May 10, 2023 (GLOBE NEWSWIRE) — NanoXplore Inc. (“NanoXplore” or “the Corporation”) (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, reported today financial results for the third quarter ended March 31, 2023. All amounts in this press release are in Canadian dollars, unless otherwise stated. HIGHLIGHTSTotal revenues of $31.6 million in Q3, up 11% compared to Q3 last year Record gross margin on revenues from customers of 18.3% in Q3, a strong improvement from 9.7% in Q3 last year Record Adjusted EBITDA* totaling $0.5 million in Q3, an improvement of $2.8 million over Q3 last year Positive cash flow from operations of $1.6 million in Q3 and $0.8 million year-to-date Total liquidity of $47.8 million as at March 31, 2023, including cash and cash equivalents of $37.4 million Total long-term debt of $8.3 million...

Continue reading

Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

Reports Record Total Revenues of $85.4 Million for Q1 2023Delivers Revenue Growth of 98%, a Record Increase YoYGAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoYNon-GAAP EPS Diluted of $0.41 Per Share, an Increase of 128% YoYAffirms Full Year Total Revenue Guidance of Between $375 Million and $385 MillionForecasts Full-Year 2023 Non-GAAP Net Income of Between $195 Million and $205 MillionFYCOMPA® Commercial and Medical Affairs Teams Onboard and Fully EngagedRecently Reported Positive Feedback From the FDA on Submission to Seek Approval of sNDA to Increase the Maximum Daily Dose of FIRDAPSE® From 80mg to 100mgContinuing Efforts to Acquire One or More Commercial or Late-Stage Products Through a Product or Company AcquisitionCORAL GABLES, Fla., May 10, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals,...

Continue reading

Crescent Capital BDC, Inc. Reports March 31, 2023 Financial Results

Declares a Second Quarter 2023 Regular Dividend of $0.41 per Share LOS ANGELES, May 10, 2023 (GLOBE NEWSWIRE) — Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) today reported net investment income of $17.5 million, or $0.54 per share, for the quarter ended March 31, 2023. Reported net asset value per share was $19.38 at March 31, 2023. On March 9, 2023, the Company completed its previously announced acquisition of First Eagle Alternative Capital BDC, Inc. (“First Eagle BDC”) (formerly NASDAQ: FCRD). The Company announced that its Board of Directors declared a regular cash dividend for the second quarter of 2023 of $0.41 per share, which will be paid on July 17, 2023 to stockholders of record as of the close of business on June 30, 2023.   Selected Financial Highlights ($ in millions, except per share...

Continue reading

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson Join Scientific Advisory Board Announces Formation of Technical Advisory Board with Deep Expertise in Gene Therapy Manufacturing SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the first quarter ended March 31, 2023. “Tenaya is making meaningful progress across multiple fronts of our business while maintaining a solid cash position. We are pleased...

Continue reading

Paycor Announces Third Quarter Fiscal Year 2023 Financial Results

Q3 Total revenues of $161.5 million, an increase of 32% year-over-year, while expanding marginsQ3 Recurring revenue of $150.8 million, an increase of 23% year-over-year, and the sixth consecutive quarter of achieving 20%+ revenue growthRaises FY’23 revenue and Adjusted operating income guidance $5 million and $3 million, respectively, year-over-year at the top end of the rangeCINCINNATI , May 10, 2023 (GLOBE NEWSWIRE) — Paycor HCM, Inc. (Nasdaq: PYCR) (“Paycor”), a leading provider of human capital management (“HCM”) software, today announced financial results for the third quarter of fiscal year 2023, which ended March 31, 2023. “Paycor posted robust 32% revenue growth year-over-year, reflecting continued strong demand for our innovative HCM suite and consistent execution of our go to market strategy as we expand nationally,”...

Continue reading

Allegro MicroSystems Reports Fourth Quarter and Fiscal Year 2023 Results

— Fourth Quarter Sales increased by 35% and GAAP Earnings Per Share (EPS) increased by 138% Year-over-Year — — Annual Sales increased by 27% and GAAP EPS increased by 56% Year-over-Year — — Continued Growth in Automotive and Industrial Drove Record Sales for the Fourth Quarter & Full Year — MANCHESTER, N.H., May 10, 2023 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro” or the “Company”) (Nasdaq:ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its fourth quarter and fiscal year 2023 which ended March 31, 2023. “We delivered a strong finish to fiscal year 2023, including record fourth quarter sales of $269 million, up 35% year-over-year. We also achieved record non-GAAP diluted...

Continue reading

Fossil Group, Inc. Reports First Quarter 2023 Financial Results

Maintains Full Year 2023 Outlook; Extends Armani and Diesel license agreements RICHARDSON, Texas, May 10, 2023 (GLOBE NEWSWIRE) — Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the first quarter ended April 1, 2023. First Quarter SummaryFirst quarter worldwide net sales decreased to $325 million, down 14% on a reported basis and 11% in constant currency, with declines in all three regions.Direct to consumer net sales up 8% in constant currency, with comparable retail sales growth of 13% and growth in all three regions. Net sales in our wholesale channels were down 20%.Operating loss of $37 million compared to $14 million a year ago. Adjusted operating loss of $25 million compared to adjusted operating loss of $11 million last year.Inventory totaled $337 million, a decrease of 13% versus a year ago;...

Continue reading

Montauk Renewables Announces First Quarter 2023 Results

PITTSBURGH, May 10, 2023 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company specializing in the management, recovery, and conversion of biogas into renewable natural gas (“RNG”), today announced financial results for the first quarter ended March 31, 2023. First Quarter Financial Highlights:Revenues of $19.2 million, decreased 40.5% as compared to the first quarter of 2022Net Loss of $3.8 million, increased 239.7% as compared to the first quarter of 2022RINs generated but unsold of 8.3 million, increased 88.1% compared to the first quarter of 2022RNG production of 1.4 million MMBtu, decreased 1.2% as compared to the first quarter of 2022Our profitability is highly dependent on the market price of Environmental Attributes, including the market price for RINs....

Continue reading

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 KANSAS CITY, Kan., May 10, 2023 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the three months ended March 31, 2023, as well as a clinical and business update. Among other highlights, the Company announced it has obtained an additional $3 million of debt financing, successfully completed the transfer of its proprietary PTR™ manufacturing processes to Societal CDMO, Inc. (Societal) and entered...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.